
commerci anim health
vaccin product also provid product
servic relat biodevic diagnost
tool genet
requir disclosur end report
zoeti okay guid
view current cl king meet event calendar coverag univers
zoeti post good beat our/street estim top
bottom line although guidanc bit step-down rel model
growth product remain strong suggest could actual provid
growth bridg product launch core thesi zoeti
grow revenu via exist companion anim product maintain
stabl perform livestock busi drive earn
growth effici initi base stabl strong cash flow
dividend share repurchas view stabl long-term grower
attract market reiter buy rate rais price target
call expand note last earn call think
approach peak dermatolog simparica next year
next wave growth come launch pain tripl
combo strength core portfolio product suggest us
perhap hole wont wide expect livestock
weak product anim product line ebb
flow
revenu ep zoeti post revenu
vs our/th street
compar quarter last year beat driven strong sale
companion anim intern adjust ep beat
street
midpoint
outlook zoeti rais revenu guidanc rang
midpoint obvious
guid surfac look littl disappoint compani beat
ad abaxi abaxa revenu
increas guidanc midpoint currenc
expect impact revenu four less
calendar day compar intern busi
ep adjust ep guidanc updat
respect
three companion drug dermatolog portfolio apoquel
cytopoint sale growth
like hit peak quarter although zoeti maintain
languag peak sale think could
quarter suggest could even simparica
revenu sequenti
year year think time play import part
pipelin zoeti actual provid color timelin tripl
combo flea tick heartworm one compani expect
product launch believ anim health ah
compani also tripl combo shouldnt
matter market huge estim zoeti under-
index categori suspect compani biologic-
base osteoarthr pain drug think recept
product would strong
abaxi abaxi acquisit close week zoeti report
revenu would tad
consensu compani hasnt made clear whether
market posit chang abaxi
model increas respect revenu
estim
also rais adjust ep
forecast respect
addit introduc respect revenu adjust
ep project note rais
estim reflect abaxi howev yet includ abaxi
revenu segment receiv clariti
price new price target base
round price-to-earnings multipl vs previous revis
adjust ep estim increas
multipl simpli reflect pass quarter
risk achiev price target
price concess competit
strong growth prospect outsid
new york citi see list compani confirm regist click
page
